AbbVie Delivers 400% Returns Beating The S&P 500 by 139%

Ten years ago, AbbVie (NYSE:ABBV) was a one-drug story. Humira, the world's best-selling medicine, threw disconnected the currency that funded everything else. Bears had been informing astir its U.S. patent cliff for years, and erstwhile biosimilars yet deed successful 2023, the cause went into freefall. Humira income dropped to conscionable $688 cardinal successful Q1 2026, down 38.6% twelvemonth implicit year, from a highest astir $21 cardinal annually.

The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and AbbVie wasn't 1 of them. Get them present FREE.

The pivot worked. Skyrizi pulled successful $4.483 cardinal successful Q1 2026 (up 30.9%) and Rinvoq added $2.119 cardinal (up 23.3%). The $63 cardinal Allergan woody successful 2020 brought Botox, Juvederm, and a neuroscience franchise that grew 26% past quarter. Full-year 2025 gross deed $61.16 billion, and absorption raised 2026 adjusted EPS guidance to $14.08 to $14.28.

Your $1,000 Turned Into $5,000 (If You Held a Decade)

1-Year Return

• Initial Investment: $1,000

• Current Value: $1,189.70

• Total Return: 18.97%

• S&P 500 (same period): $1,281.50 (28.15%)

5-Year Return

• Initial Investment: $1,000

• Current Value: $2,317.40

• Total Return: 131.74%

• Annualized Return: astir 18%

• S&P 500 (same period): $1,813.80 (81.38%)

10-Year Return

• Initial Investment: $1,000

• Current Value: $5,006.40

• Total Return: 400.64%

• Annualized Return: astir 17%

• S&P 500 (same period): $3,612.20 (261.22%)

The 10-year fig is the headline. AbbVie crushed the scale implicit the agelong haul portion paying retired a rising dividend the full clip (the quarterly payout went from $0.57 successful 2016 to $1.73 today, and that's earlier reinvestment). Holding done 2023, erstwhile Humira fears peaked, was the hard part. The 1-year lag versus the S&P reflects a broader marketplace rally that near antiaircraft pharma behind.

The Bull Case, With One Condition

I'd enactment $1,000 into AbbVie contiguous if I wanted income positive a credible maturation engine, and I believed Skyrizi and Rinvoq tin transportation the franchise until the adjacent question of pipeline assets, including the non-incretin obesity programme ABBV-295, matures. The combined Skyrizi-Rinvoq tally complaint already exceeds Humira's peak, and the 3.1% dividend output with guardant P/E adjacent 15 gives maine a borderline of safety.